Figure 2
Hematologic dysfunction in the mouse models with the loss of MYSM1 DUB catalytic activity. Hematology analyses were conducted on the blood of (A) Mysm1+/+, Mysm1−/−, and Mysm1DN/DN mice, and (B) CreERT2-transgenic tamoxifen-treated mice of Mysm1fl/+, Mysm1fl/fl, and Mysm1fl/DN genotypes. Data is from (A) 3–8 mice per genotype consolidated from two independent experiments, or (B) 5–6 mice per genotype consolidated from two independent experiments. Bars represent means ± SEM; statistical analysis with ANOVA comparing each group to the control, *p < 0.05, **p < 0.01, ***p < 0.001, NS—not significant; MCV—mean corpuscular volume.
